DEVELOP OF ANTIBODY FRAGM AS CONTR AGT FOR MRI OF ALZH?S DIS AMYLOID PLAQUES

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 将治疗性或诊断性蛋白质靶向神经系统的能力受到血脑/神经屏障存在的限制。在这个项目中，我们正在测试的假设，即针对纤维状人A 42的单克隆抗体（IgG4.1）的F（ab 2）2片段的修饰可以用于使用高场强磁共振显微成像（MRMI）（9.4 T）进行阿尔茨海默病（AD）中淀粉样蛋白斑块的分子成像。这种造影剂在AD转基因小鼠体内对斑块成像的能力可能导致人类AD的早期诊断，并且还提供了目前正在开发的抗淀粉样蛋白疗法的疗效的直接测量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ability to target therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood-brain/nerve barriers. In this project we are testing the hypothesis that modifications of an F(ab2)2 fragment of a monoclonal antibody (IgG4.1) against fibrillar human A¿42 can be used for the molecular imaging of amyloid plaques in Alzheimer's disease (AD) using high field strength magnetic resonance microimaging (MRMI) (9.4 T). The ability of this contrast agent to image plaques in vivo in AD transgenic mice may lead to early diagnosis of AD in humans and also provide a direct measure of the efficacy of anti-amyloid therapies currently being developed.